1

PCSK9 targeting for the treatment of dyslipidemia

1

1. reduction of the PCSK9 mRNA

2. Inhibition of the LDLR/PCSK9 binding at the plasma membrane

3. Inhibition of the PCSK9 processing

4. Inhibition of the intracellular LDLR/PCSK9 binding

Tibolla G, et al., Nutrition, Metabolism & Cardiovascular Diseases (2011, doi:10.1016/j.numecd.2011.06.002